Polycystic ovarian syndrome increases prevalence of concentric hypertrophy in normotensive obese women.
Adult
Blood Glucose
Blood Pressure
Cholesterol
/ blood
Cholesterol, HDL
/ blood
Cholesterol, LDL
/ blood
Echocardiography
Female
Heart Failure, Diastolic
/ complications
Heart Ventricles
/ diagnostic imaging
Humans
Hypertrophy, Left Ventricular
/ blood
Obesity
/ blood
Polycystic Ovary Syndrome
/ blood
Triglycerides
/ blood
Ventricular Function, Left
/ physiology
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
08
2021
accepted:
15
01
2022
entrez:
25
2
2022
pubmed:
26
2
2022
medline:
11
3
2022
Statut:
epublish
Résumé
It remains unclear as to whether polycystic ovary syndrome (PCOS) is an additional risk factor in the development of left ventricular (LV) hypertrophy in obese women. In the current study, we provide clarity on this issue by rigorously analysing patient LV geometry beyond the basic clinical measures currently used. Importantly, the cohort contained only normotensive patients that would normally be deemed low risk with no further intervention required. The study comprised 24 obese women with PCOS and 29 obese Control women. Transthoracic echocardiography was used to evaluate LV structure/function. Basic clinical and metabolic data were collected for each participant consisting of age, BMI, blood pressure, fasting glucose, LDL-C, HLD-C, cholesterol and triglyceride levels. Exclusion criteria; BMI < 30 g/m2, type 2 diabetes, hypertension. Both groups exhibited concentric remodelling of the LV posterior wall at a prevalence of ~20%, this associated with grade 1 diastolic dysfunction. Estimated LV mass/height2.7 was increased patients with PCOS (45 ± 2.2 vs 37 ± 1.6) with 33% exhibiting LV mass/height2.7 above ASE guidelines, compared to 7% in Controls. Furthermore, 25% of patients with PCOS were characterised with concentric hypertrophy, an alteration in LV geometry that was not observed in the Control group. To our knowledge, this is the first study to assess LV geometric patterns in obese women with PCOS. The results suggest that obese women with PCOS are at greater risk of concentric hypertrophy than obese only women and provide justification for additional cardiovascular risk assessment in normotensive obese/PCOS women.
Sections du résumé
BACKGROUND
It remains unclear as to whether polycystic ovary syndrome (PCOS) is an additional risk factor in the development of left ventricular (LV) hypertrophy in obese women. In the current study, we provide clarity on this issue by rigorously analysing patient LV geometry beyond the basic clinical measures currently used. Importantly, the cohort contained only normotensive patients that would normally be deemed low risk with no further intervention required.
METHODS
The study comprised 24 obese women with PCOS and 29 obese Control women. Transthoracic echocardiography was used to evaluate LV structure/function. Basic clinical and metabolic data were collected for each participant consisting of age, BMI, blood pressure, fasting glucose, LDL-C, HLD-C, cholesterol and triglyceride levels. Exclusion criteria; BMI < 30 g/m2, type 2 diabetes, hypertension.
RESULTS
Both groups exhibited concentric remodelling of the LV posterior wall at a prevalence of ~20%, this associated with grade 1 diastolic dysfunction. Estimated LV mass/height2.7 was increased patients with PCOS (45 ± 2.2 vs 37 ± 1.6) with 33% exhibiting LV mass/height2.7 above ASE guidelines, compared to 7% in Controls. Furthermore, 25% of patients with PCOS were characterised with concentric hypertrophy, an alteration in LV geometry that was not observed in the Control group.
CONCLUSIONS
To our knowledge, this is the first study to assess LV geometric patterns in obese women with PCOS. The results suggest that obese women with PCOS are at greater risk of concentric hypertrophy than obese only women and provide justification for additional cardiovascular risk assessment in normotensive obese/PCOS women.
Identifiants
pubmed: 35213570
doi: 10.1371/journal.pone.0263312
pii: PONE-D-21-26492
pmc: PMC8880941
doi:
Substances chimiques
Blood Glucose
0
Cholesterol, HDL
0
Cholesterol, LDL
0
Triglycerides
0
Cholesterol
97C5T2UQ7J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0263312Déclaration de conflit d'intérêts
he authors have declared that no competing interests exist.
Références
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
Oxid Med Cell Longev. 2021 Aug 31;2021:8862878
pubmed: 34512871
Fertil Steril. 2004 Jan;81(1):19-25
pubmed: 14711538
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Can J Cardiol. 2017 Jul;33(7):860-871
pubmed: 28579160
J Clin Endocrinol Metab. 2012 Dec;97(12):4656-62
pubmed: 23012389
Hypertension. 2004 Apr;43(4):731-8
pubmed: 15007041
Am J Cardiol. 2007 Nov 1;100(9):1460-4
pubmed: 17950808
Rev Obstet Gynecol. 2009 Fall;2(4):232-9
pubmed: 20111659
J Am Heart Assoc. 2015 Sep 15;4(9):e002188
pubmed: 26374295
J Endocrinol. 2012 Jul;214(1):1-10
pubmed: 22493003
Ann Intern Med. 1991 Mar 1;114(5):345-52
pubmed: 1825164
JACC Cardiovasc Imaging. 2015 Jun;8(6):656-65
pubmed: 25981507
Cardiovasc Diabetol. 2017 Feb 8;16(1):21
pubmed: 28178970
Hum Reprod. 2001 Sep;16(9):1995-8
pubmed: 11527911